The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan

We love to hear from our listeners. Send us a message.

Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf’ cell therapy products. They cover Artiva's "manufacturing first" approach to enabling scalable NK cell production, and much more.

Subscribe to the podcast!
Apple | Spotify | YouTube